RCS - Solvonis Therapeutic - Media Coverage: Small Cap Idea profile

Solvonis TherapeuticsAnnouncement

13/08/2025 15:15

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250813:nRSM2234Va&default-theme=true

RNS Number : 2234V  Solvonis Therapeutics PLC  13 August 2025

13 August 2025
Solvonis Therapeutics plc

("Solvonis" or the "Company")

Media Coverage: Small Cap Idea profile in ThisIsMoney.co.uk / Daily Mail.

 

Solvonis Therapeutics plc (LSE: SVNS), a clinical-stage biopharmaceutical
company developing novel medicines for addiction and mental health disorders,
notes the publication of an article on ThisIsMoney.co.uk (Daily Mail online)
titled "SMALL CAP IDEA: Ketamine drip therapy firm is taking on alcoholism".

The article, written by Ian Lyall of Proactive Investors, highlights:

·      Solvonis' recent acquisition of Awakn Life Sciences and the
integration of its development pipeline.

·      The Company's lead programme, SVN-001, in Phase III clinical
trials for severe AUD for the UK and EU AUD markets, combining ketamine
infusion with Cognitive Behavioural Therapy (CBT).

·      The Company's second programme, SVN-002, targeting the US AUD
market via the FDA's 505(b)(2) regulatory pathway, referencing Johnson &
Johnson's approved esketamine product Spravato®.

·      Sector valuation comparisons with US-listed peers and recent
M&A activity highlighting strategic interest in novel mental health
therapeutics.

·      The full article can be accessed here:
https://www.thisismoney.co.uk/money/markets/article-14996499/SMALL-CAP-IDEA-Ketamine-drip-therapy-firm-taking-alcoholism.html
(https://www.thisismoney.co.uk/money/markets/article-14996499/SMALL-CAP-IDEA-Ketamine-drip-therapy-firm-taking-alcoholism.html)

 

Enquiries:

Solvonis Therapeutics plc

Anthony Tennyson, CEO & Executive Director

anthony@solvonis.com

Allenby Capital Limited (Financial Adviser and Joint Broker)

Nick Naylor / Nick Athanas / Ashur Joseph (Corporate Finance)

Guy McDougall (Sales & Corporate Broking)

+44 (0) 20 3328 5656

Singer Capital Markets (Joint Broker)

Phil Davies

+44 (0) 20 7496 3000

About Solvonis Therapeutics plc

Solvonis Therapeutics plc (LSE: SVNS) is a clinical-stage biopharmaceutical
company developing novel medicines for addiction and mental health disorders.
Headquartered in London and listed on the main market of the London Stock
Exchange, Solvonis is advancing a differentiated pipeline of repurposed and
novel compounds targeting high-burden neuropsychiatric conditions with
significant unmet need.

The Company's lead programmes address Alcohol Use Disorder (AUD) and
Post-Traumatic Stress Disorder (PTSD)-conditions affecting over 80 million
people across the UK, US, and EU4. Its lead asset, SVN-001, is currently in
Phase 3 for severe AUD in Europe and the UK. SVN-002 is preparing for a Phase
2b trial in the US targeting moderate to severe AUD. Solvonis also has a
preclinical PTSD programme leveraging novel serotonin-dopamine modulators
designed to enhance pro-social behaviour and long-term outcomes.

In addition, Solvonis is advancing an AI-supported discovery platform built on
a proprietary CNS compound library, with initial focus on depression and
stimulant use disorders. This initiative expands the Company's R&D
pipeline into earlier-stage innovation while maintaining strategic focus on
comorbid and underserved neuropsychiatric conditions.

With a capital-efficient model, dual development strategy, and near-term
partnering opportunities, Solvonis is positioned to generate value through
innovation in neuropsychiatry.

solvonis.com (https://solvonis.com) | LinkedIn
(https://www.linkedin.com/company/solvonis) | X (Twitter)
(https://x.com/Solvonis)

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAGPUUURUPAGCW